SCH 23390 HCl | CAS#125941-87-9 | dopamine receptor antagonist

MedKoo Cat#: 526284 | Name: SCH 23390 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SCH 23390 is a potent dopamine receptor antagonist (Ki values are 0.2 nM and 0.3 nM at D1 and D5 receptor sub-types, respectively). SCH 23390 is also an agonist at 5-HT1C and 5-HT2C receptors in vitro (Ki values are 6.3 nM and 9.3 nM respectively).

Chemical Structure

SCH 23390 HCl

CAS#125941-87-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 526284

Name: SCH 23390 HCl

CAS#: 125941-87-9 (HCl)

Chemical Formula: C17H19Cl2NO

Exact Mass: 0.0000

Molecular Weight: 324.25

Elemental Analysis: C, 62.97; H, 5.91; Cl, 21.87; N, 4.32; O, 4.93

Price and Availability

Size	Price	Availability
5mg	USD 90.00	Ready to Ship
10mg	USD 150.00	Ready to Ship
25mg	USD 250.00	Ready to Ship
50mg	USD 450.00	Ready to Ship
100mg	USD 750.00	Ready to Ship
200mg	USD 1,350.00	Ready to Ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

125941-87-9 (HCl) 87075-17-0 (free base) 87134-87-0 (maleate)

Synonym

SCH 23390 HCl; SCH-23390 HCl; SCH23390 HCl; SCH 23390 hydrochloride; SCH-23390 hydrochloride; SCH23390 hydrochloride

IUPAC/Chemical Name

(R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol hydrochloride

InChi Key

OYCAEWMSOPMASE-XFULWGLBSA-N

InChi Code

InChI=1S/C17H18ClNO.ClH/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12;/h2-6,9-10,15,20H,7-8,11H2,1H3;1H/t15-;/m1./s1

SMILES Code

OC1=C(Cl)C=C2CCN(C)C[C@H](C3=CC=CC=C3)C2=C1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#Y23X12M06

QC Data

View QC data: current batch, Lot#Y23X12M06

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

SCH 23390 HCl is a dopamine D1-like receptor antagonist with Kis of 0.2 nM and 0.3 nM for the D1 and D5 receptor, respectively. SCH 23390 HCl is a human 5-HT2C receptor agonist with a Ki of 9.3 nM. SCH 23390 HCl inhibits GIRK channels with an IC50 of 268 nM.

In vitro activity:

In this study, SCH 23390 was discovered to inhibit GIRK channels, independent of receptor activation. The inhibition is selective, affecting GIRK currents induced by somatostatin or D3 dopamine receptors. SCH 23390 can depolarize membrane potential and induce action potentials in cells. Reference: Mol Pharmacol. 2002 Jul;62(1):119-26. https://pubmed.ncbi.nlm.nih.gov/12065762/

In vivo activity:

SCH 23390 may have use in addiction treatment research. In a saccharin seeking rat model, systemic SCH 23390 injections reduced saccharin seeking and reduced saccharin seeking persistence. Reference: Appetite. 2016 Oct 1;105:8-13. https://pubmed.ncbi.nlm.nih.gov/27179937/

	Solvent	mg/mL	mM
Solubility
	Water	28.6	88.11

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 324.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kuzhikandathil EV, Oxford GS. Classic D1 dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) directly inhibits G protein-coupled inwardly rectifying potassium channels. Mol Pharmacol. 2002 Jul;62(1):119-26. doi: 10.1124/mol.62.1.119. PMID: 12065762. 2. Millan MJ, Newman-Tancredi A, Quentric Y, Cussac D. The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology (Berl). 2001 Jun;156(1):58-62. doi: 10.1007/s002130100742. PMID: 11465634. 3. Japarin RA, Harun N, Hassan Z, Müller CP. The dopamine D1 receptor antagonist SCH-23390 blocks the acquisition, but not expression of mitragynine-induced conditioned place preference in rats. Behav Brain Res. 2023 Sep 13;453:114638. doi: 10.1016/j.bbr.2023.114638. Epub 2023 Aug 22. PMID: 37619769. 4. Aoyama K, Barnes J, Koerber J, Glueck E, Dorsey K, Eaton L, Grimm JW. Systemic injection of the DAD1 antagonist SCH 23390 reduces saccharin seeking in rats. Appetite. 2016 Oct 1;105:8-13. doi: 10.1016/j.appet.2016.05.008. Epub 2016 May 11. PMID: 27179937; PMCID: PMC4980176.

In vitro protocol:

In vivo protocol:

1. Japarin RA, Harun N, Hassan Z, Müller CP. The dopamine D1 receptor antagonist SCH-23390 blocks the acquisition, but not expression of mitragynine-induced conditioned place preference in rats. Behav Brain Res. 2023 Sep 13;453:114638. doi: 10.1016/j.bbr.2023.114638. Epub 2023 Aug 22. PMID: 37619769. 2. Aoyama K, Barnes J, Koerber J, Glueck E, Dorsey K, Eaton L, Grimm JW. Systemic injection of the DAD1 antagonist SCH 23390 reduces saccharin seeking in rats. Appetite. 2016 Oct 1;105:8-13. doi: 10.1016/j.appet.2016.05.008. Epub 2016 May 11. PMID: 27179937; PMCID: PMC4980176.

1: Aoyama K, Barnes J, Koerber J, Glueck E, Dorsey K, Eaton L, Grimm JW. Systemic injection of the DAD1 antagonist SCH 23390 reduces saccharin seeking in rats. Appetite. 2016 Oct 1;105:8-13. doi: 10.1016/j.appet.2016.05.008. PubMed PMID: 27179937; PubMed Central PMCID: PMC4980176. 2: Tian L, Qin X, Sun J, Li X, Wei L. Differential effects of co-administration of oxotremorine with SCH 23390 on impulsive choice in high-impulsive rats and low-impulsive rats. Pharmacol Biochem Behav. 2016 Mar;142:56-63. doi: 10.1016/j.pbb.2016.01.001. PubMed PMID: 26772787. 3: Rauhut AS. Timing of SCH 23390 administration influences extinction of conditioned hyperactivity in mice. Behav Pharmacol. 2016 Feb;27(1):73-6. doi: 10.1097/FBP.0000000000000188. PubMed PMID: 26292185. 4: Tran S, Nowicki M, Muraleetharan A, Chatterjee D, Gerlai R. Differential effects of acute administration of SCH-23390, a D₁ receptor antagonist, and of ethanol on swimming activity, anxiety-related responses, and neurochemistry of zebrafish. Psychopharmacology (Berl). 2015 Oct;232(20):3709-18. doi: 10.1007/s00213-015-4030-y. PubMed PMID: 26210378. 5: Kozhevnikova LM, Mesitov MV, Moskovtsev AA. [Agonists of 5HT2C-receptors SCH 23390 and MK 212 incresase the force of rat aorta contraction in the presence of vasopressin and angiotensin II]. Patol Fiziol Eksp Ter. 2014 Oct-Dec;(4):17-29. Russian. PubMed PMID: 25980223. 6: Fedotova YO, Sapronov NS. Effects of SCH-23390 and sulpiride on active avoidance in ovariectomized rats treated with a low dose of 17β-estradiol. Bull Exp Biol Med. 2014 Mar;156(5):612-4. doi: 10.1007/s10517-014-2407-2. PubMed PMID: 24770740. 7: Fedotova J. Effects of SCH-23390 in combination with a low dose of 17β-estradiol on anxiety-like behavior in ovariectomized rats. Biomed Res Int. 2014;2014:847821. doi: 10.1155/2014/847821. PubMed PMID: 24707499; PubMed Central PMCID: PMC3953507. 8: An XL, Zheng XG, Liang J, Bai YJ. Corticosterone combined with intramedial prefrontal cortex infusion of SCH 23390 impairs the strong fear response in high-fear-reactivity rats. Psych J. 2013 Apr;2(1):1-10. doi: 10.1002/pchj.5. PubMed PMID: 26272859. 9: Leung K. (R)-(+)-8-Chloro-2,3,4,5-tetrahydro-3-[(11)C]methyl-5-phenyl-1H-3-benzazepin-7-ol ([(11)C]SCH 23390). 2005 Nov 22 [updated 2012 Jan 16]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK23252/ PubMed PMID: 20641454. 10: Goodwin RJ, Mackay CL, Nilsson A, Harrison DJ, Farde L, Andren PE, Iverson SL. Qualitative and quantitative MALDI imaging of the positron emission tomography ligands raclopride (a D2 dopamine antagonist) and SCH 23390 (a D1 dopamine antagonist) in rat brain tissue sections using a solvent-free dry matrix application method. Anal Chem. 2011 Dec 15;83(24):9694-701. doi: 10.1021/ac202630t. PubMed PMID: 22077717. 11: Galistu A, D'Aquila PS. Effect of the dopamine D1-like receptor antagonist SCH 23390 on the microstructure of ingestive behaviour in water-deprived rats licking for water and NaCl solutions. Physiol Behav. 2012 Jan 18;105(2):230-3. doi: 10.1016/j.physbeh.2011.08.006. PubMed PMID: 21864553. 12: Schlenker EH, Schultz HD. Hypothyroidism attenuates SCH 23390-mediated depression of breathing and decreases D1 receptor expression in carotid bodies, PVN and striatum of hamsters. Brain Res. 2011 Jul 15;1401:40-51. doi: 10.1016/j.brainres.2011.05.034. PubMed PMID: 21669406; PubMed Central PMCID: PMC3124595. 13: Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, Tanaka S, Katsuki I, Matsushita S, Tanaka Y. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol. 2011 Mar 15;186(6):3745-52. doi: 10.4049/jimmunol.1002475. PubMed PMID: 21307293. 14: Rodrigues LC, Conti CL, Nakamura-Palacios EM. Clozapine and SCH 23390 prevent the spatial working memory disruption induced by Δ9-THC administration into the medial prefrontal cortex. Brain Res. 2011 Mar 25;1382:230-7. doi: 10.1016/j.brainres.2011.01.069. PubMed PMID: 21281616. 15: Zarrindast MR, Honardar Z, Sanea F, Owji AA. SKF 38393 and SCH 23390 inhibit reuptake of serotonin by rat hypothalamic synaptosomes. Pharmacology. 2011;87(1-2):85-9. doi: 10.1159/000323232. PubMed PMID: 21242715. 16: Benaliouad F, Zhornitsky S, Rompré PP. Evidence that the reward attenuating effect of the D1-like antagonist, SCH-23390, is not mediated by its agonist action at the 5-HT2c receptors. Behav Brain Res. 2011 Mar 1;217(2):467-71. doi: 10.1016/j.bbr.2010.09.023. PubMed PMID: 20920533. 17: Smith GP, Smith JC. The inhibitory potency of SCH 23390 and raclopride on licking for sucrose increases across brief-access tests. Physiol Behav. 2010 Oct 5;101(3):315-9. doi: 10.1016/j.physbeh.2010.05.013. PubMed PMID: 20515702. 18: Dias FR, Carey RJ, Carrera MP. Apomorphine-induced context-specific behavioural sensitization is prevented by the D1 antagonist SCH-23390 but potentiated and uncoupled from contextual cues by the D2 antagonist sulpiride. Psychopharmacology (Berl). 2010 Apr;209(2):137-51. doi: 10.1007/s00213-009-1768-0. PubMed PMID: 20177884. 19: Avgustinovich DF, Alekseyenko OV. [3H]SCH 23390 binding in various brain regions of C57BL/6J mice with repeated experience of victory or social defeat in agonistic interactions. Physiol Res. 2010;59(3):455-8. PubMed PMID: 19681653. 20: Zawilska JB, Lorenc A, Berezińska M. Regulation of serotonin N-acetyltransferase activity in the chick pineal gland by UV-A and white light: role of MK-801- and SCH 23390-sensitive retinal signals. Pharmacol Rep. 2007 Jul-Aug;59(4):408-13. PubMed PMID: 17901569.